ARS Pharmaceuticals (SPRY) Interest Coverage Ratio (2026)

ARS Pharmaceuticals' (SPRY) quarterly Interest Coverage Ratio came in at 24.64 in Q1 2026.

ARS Pharmaceuticals (SPRY) Interest Coverage Ratio (2026) Analysis & Trends

ARS Pharmaceuticals has disclosed Interest Coverage Ratio across 1 years of filings, most recently posting 24.64 for Q1 2026.

Interest Coverage Ratio for Q1 2026 came in at 24.64, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was 24.15 (changed N/A YoY), and the FY2025 annual result was 13.85, changed N/A from the prior year.
Interest Coverage Ratio came in at 24.64 for Q1 2026 at ARS Pharmaceuticals.
In the past five years, Interest Coverage Ratio ranged from a high of 24.64 in Q1 2026 to a low of 24.64 in Q1 2026.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Interest Cover (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	3.58
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	11.50
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-258.33
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	547.67
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	-
9	Abivax	91.96 Bn	91.96 Bn	-	11.79
10	ARS Pharmaceuticals	954.24 Mn	753.27 Mn	-	-24.64

Historic Data

Download Data

Date	Value
Mar 31, 2026	-24.64